Human papillomavirus (HPV) DNA methylation changes in HPV-associated head and neck cancer.
Journal
Carcinogenesis
ISSN: 1460-2180
Titre abrégé: Carcinogenesis
Pays: England
ID NLM: 8008055
Informations de publication
Date de publication:
11 03 2024
11 03 2024
Historique:
received:
06
07
2023
revised:
23
10
2023
accepted:
23
01
2024
medline:
12
3
2024
pubmed:
25
1
2024
entrez:
25
1
2024
Statut:
ppublish
Résumé
Despite the rising incidence, currently, there are no early detection methods for HPV-driven HNC (HPV-HNC). Cervical cancer studies suggest that HPV DNA methylation changes can be used as a biomarker to discriminate cancer patients from HPV-infected individuals. As such, this study was designed to establish a protocol to evaluate DNA methylation changes in HPV late genes and long control region (LCR) in saliva samples of HPV-HNC patients and HPV-positive controls. Higher methylation levels were detected in HPV late genes (L1 and L2) in both tumour and saliva samples of HPV-HNC patients compared with HPV-positive controls. Moreover, methylation patterns between tumours and corresponding saliva samples were observed to have a strong correlation (Passing-Bablok regression analysis; τ = 0.7483, P < 0.0001). Considering the differences between HNC and controls in methylation levels in late genes, and considering primer amplification efficiencies, 13 CpG sites located at L1 and L2 genes were selected for further evaluation. A total of 18 HNC saliva samples and 10 control saliva samples were assessed for the methylation levels in the selected sites. From the CpG sites evaluated statistically significant differences were identified for CpG sites at L2-CpG 6 (P = 0.0004), L1-CpG 3 (P = 0.0144), L1-CpG 2 (P = 0.0395) and L2-CpG 19 (P = 0.0455). Our pilot data indicate that higher levels of DNA methylation in HPV late genes are indicative of HPV-HNC risk, and it is a potential supplementary biomarker for salivary HPV detection-based HPV-HNC screening.
Identifiants
pubmed: 38270218
pii: 7589235
doi: 10.1093/carcin/bgae001
pmc: PMC10925951
doi:
Substances chimiques
DNA, Viral
0
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
140-148Subventions
Organisme : National Health and Medical Research Council
ID : APP 2012560
Organisme : University Grants Commission
Informations de copyright
© The Author(s) 2024. Published by Oxford University Press.
Références
J Mol Diagn. 2021 Oct;23(10):1334-1342
pubmed: 34325059
Epigenetics. 2013 Sep;8(9):953-61
pubmed: 23867721
Head Neck. 2019 May;41(5):1484-1489
pubmed: 30582230
J Virol. 1996 Oct;70(10):7233-5
pubmed: 8794373
JNCI Cancer Spectr. 2020 Jun 05;4(5):pkaa047
pubmed: 33225205
Ann Oncol. 2017 Dec 01;28(12):3065-3069
pubmed: 29059337
Int J Cancer. 2016 Jun 1;138(11):2745-51
pubmed: 26790008
Clin Epigenetics. 2020 Apr 21;12(1):57
pubmed: 32317020
Cancer Biomark. 2015;15(5):669-75
pubmed: 26406956
Int J Cancer. 2007 May 15;120(10):2165-9
pubmed: 17278110
Clin Cancer Res. 2018 May 1;24(9):2194-2202
pubmed: 29420222
Biomolecules. 2020 Feb 03;10(2):
pubmed: 32028653
N Engl J Med. 2020 Jan 2;382(1):60-72
pubmed: 31893516
Gynecol Oncol. 2011 Dec;123(3):597-604
pubmed: 21911249
Int J Cancer. 2020 Feb 15;146(4):1018-1030
pubmed: 31304592
Cancer. 2017 Jun 15;123(12):2219-2229
pubmed: 28346680
Int J Cancer. 2019 May 15;144(10):2587-2595
pubmed: 30412281
Cancer Sci. 2020 Oct;111(10):3854-3861
pubmed: 32713038
Diagnostics (Basel). 2017 Mar 01;7(1):
pubmed: 28257064
J Virol. 2004 Dec;78(23):12762-72
pubmed: 15542628
Cancer. 2018 May 1;124(9):1859-1866
pubmed: 29499070
Cancers (Basel). 2019 Apr 03;11(4):
pubmed: 30987261
Cells. 2020 May 31;9(6):
pubmed: 32486347